With its many ties with the Biden administration, many see the next four years as golden ones for the company. Thomas Niel, a contributor to InvestorPlace, has written single stock analysis since 2016. A high-level overview of Jaguar Health, Inc. (JAGX) stock. Meme Stocks: Zomedica (ZOM) Source: didesign021 / Shutterstock.com With its veterinary diagnostic product Truforma, early-stage biotech company Zomedica could finally have its day in the sun. Buy-hold investing in broad diversified portfolios produces the largest lifetime returns.“ It may be fun to dabble in meme stocks. The presentation reported the findings on measures of physical and social function as well as work productivity, which revealed statistically significant improvements in several of the measures SAN FRANCISCO, CA / ACCESSWIRE / June 12, 2018 /  Napo Pharmaceuticals, Inc. SAN FRANCISCO, CA / ACCESSWIRE / June 1, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the, Mr. Griffing to Lead Commercialization Efforts for Mytesi, Jaguar's FDA-Approved, First-in-Class Drug Product SAN FRANCISCO, CA / ACCESSWIRE / May 29, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on, Company Management to Host Conference Call Monday, May 21 st at 4:30 p.m. Eastern Time for Investors and Analysts SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on, Merce  Series Creator and Cast Members Will Appear with Napo Pharmaceuticals, the Lead Sponsor of  Merce  Season 2, at AIDS Walk New York in Central Park on May 20, 2018 SAN FRANCISCO, CA / ACCESSWIRE / May 15, 2018 /  Napo Pharmaceuticals, Inc. (Napo), a human health company developing and, Mytesi for HIV-related Diarrhea Now on ADAP Formularies in 22 States SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived. Given the fundamentals fail to match up with today’s valuation, EXPR stock is a prime example of a meme stock to avoid. 3, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and, National Sales Force Will Promote and Provide Samples of Mytesi™ to HIV Healthcare Providers SAN FRANCISCO--( BUSINESS WIRE )--Napo Pharmaceuticals, Inc., a company focused on the development and commercialization of proprietary pharmaceuticals for the global marketplace from plants traditionally. This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time . 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, SAN FRANCISCO --(BUSINESS WIRE)--Feb. 22, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today the, Advantages as an Alternative Approach to the Management of Gastrointestinal Ulcers in Horses SAN FRANCISCO --(BUSINESS WIRE)--Feb. 16, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class, Progress on Rx Product Pipeline SAN FRANCISCO --(BUSINESS WIRE)--Feb. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, today announced the, SAN FRANCISCO , Feb. 3, 2016 /PRNewswire/ --   Jaguar Animal Health, Inc. (Nasdaq: JAGX) , an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced today the pricing of an, SAN FRANCISCO --(BUSINESS WIRE)--Jan. 28, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced, SAN FRANCISCO --(BUSINESS WIRE)--Jan. 7, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 22, 2015-- Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today that it has initiated a pivotal, Study is First Step in Jaguar’s Development Program for a Crofelemer Drug Product Candidate for Treatment of Diarrhea Associated with Acute Colitis in Horses SAN FRANCISCO --(BUSINESS WIRE)--Dec. 21, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 18, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced positive, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 16, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 15, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced, SAN FRANCISCO --(BUSINESS WIRE)--Dec. 3, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has. 3, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has named Folkert Kamphuis to its board, SAN FRANCISCO --(BUSINESS WIRE)--May 13, 2015-- Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the pricing of its initial public offering of, One Application Covers the Combined Use of Croton lechleri-derived Products and Rifaximin to Address Diarrhea Symptoms The Second is for the Prebiotic Benefit of Crofelemer and Croton lechleri-derived Products in Dairy Calves and Other Animals San Francisco, CA (March 4, 2015): Jaguar Animal, San Francisco, CA (February 26, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has entered into a supply and distribution. 27, 2017-- Napo Pharmaceuticals, Inc. , a human health company developing and commercializing novel gastrointestinal, SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that the Organic, Neonorm.com allows online ordering and features in-depth product information for dairy and beef farmers, foal owners and veterinarians to help drive sales SAN FRANCISCO --(BUSINESS WIRE)--Jun. Trading for around $3 per share in mid-January, shares topped $64 per share by month’s end. Press Release reported on 01/29/21 that Thinking about buying stock in Nokia, Sorrento Therapeutics, BlackBerry, Viveve Medical, or Jaguar Health? And, as its epic rise made headlines across the globe, those late to the party hopped along for the ride.InvestorPlace - Stock Market News, Stock Advice & Trading Tips But, hopping on the bandwagon can be a risky move for retail investors. SAN FRANCISCO --(BUSINESS WIRE)--Apr. ET on InvestorPlace.com Jaguar Health Isn’t a Healthy Investment, but It Could Be a Profitable One Add in its potential as either an acquirer, or acquiree, and I concede its not just irrational euphoria that’s sent this penny stock from under $1 per share to today’s prices. It’s debatable. If the company falls short of growth projections, it’s meme stock status could take a hit. But, with this equity raise came heavy dilution. Jaguar Health Inc. NASDAQ Updated Feb 17, 2021 12:59 AM JAGX 2.86 0.00 (0.00%). The Dragon SPAC is a newly formed initiative expected to be incorporated in Italy, with lead sponsorship by Josh Mailman. With medical experts saying long-haul Covid could be a health crisis post-pandemic, Jaguar may have a massive opportunity here. I wouldn’t count on it. Speculators online took this possibility, and ran with it. @ajitlama1983 Napo is a sub of Jag Health. Cashing out to the tune of $44 million, they’ve taken the money and ran. Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc. Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea, Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI, Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China, Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer, Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern, Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea, Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use, Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York, Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer, Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico, Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel, Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern, Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director, Jaguar Health Achieves Statistically Significant Top Line Results in Study Evaluating Crofelemer for Treatment of Diarrhea Related to Targeted Cancer Therapy, Jaguar Health Appoints Carol Lizak Chief Accounting Officer, Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results, Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website, Jaguar Health's CDMO Improves Manufacturing Processes to Support the Expanded Crofelemer Manufacturing Volume Expected to be Required for Potential Expanded Indications, Including a Potential Indication for Cancer Therapy-related Diarrhea, Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event at 3 p.m. Eastern Today, Jaguar Health Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option, Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering, Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million, Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea, Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million, Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome, Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors, Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication, Jaguar Health, Inc. This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients and severe acute watery diarrhea SAN FRANCISCO, CA / ACCESSWIRE / January 20, 2021 /   Jaguar Health, Inc. SAN FRANCISCO, CA / ACCESSWIRE / January 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor webcast and a recap of the key points from the presentation. Yet, at around $17 per share, it’s still overpriced at today’s prices. What is a Value Stock? However, this remains a “wait-and-see” opportunity. Stock analysis for Jaguar Health Inc (JAGX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Since it’s still at the pre-revenue stage, it’s tough to use traditional valuation metrics on it. REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time . In the long term, the company is likely worth only a fraction of what it trades for today. 30, 2015-- Jaguar Animal Health, Inc. (Nasdaq:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it was added, Results Support Study to Investigate Potential Prebiotic Effect on Calf Gut Microbiome SAN FRANCISCO --(BUSINESS WIRE)--Jun. Announces 1-for-15 Reverse Stock Split, Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals, Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders, ''Under Pressure'' Episode of Merce Uses Comedy to Help People Living with HIV Talk About Diarrhea, Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea, Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi, Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV, Jaguar Health Appoints Jonathan B. Siegel to Board of Directors, Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi, FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs, Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program, Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (August–December 2017), Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results, Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim, Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in Horses, New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence, Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017, Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline, Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC, Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals, Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription Drug, Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million, Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time, Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time, Jaguar Health Enters Non-Binding Agreement of Terms to Issue a Secured Convertible Note to Iliad Research and Trading, L.P. (an Affiliate of Chicago Venture Partners, L.P.), as Jaguar Expands Commercial Efforts for Mytesi, Jaguar Health Receives Approval from The American Association of Veterinary State Boards RACE Committee for Continuing Education Program for Veterinarians and Veterinary Technicians on Diarrhea in Foals, Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug, Jaguar Health Subsidiary Napo Pharmaceuticals Launches National “Keep Your Pants On… Unless You Don’t Want To” Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living With HIV/AIDS, Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo’s FDA-approved Human Prescription Drug, Napo Pharmaceuticals Endorses Prevention Access Campaign’s U=U Consensus Statement for People Living With HIV/AIDS (PLWHA), Jaguar Health Prices $4.25 Million Public Offering of Common Stock, Jaguar Subsidiary Napo Pharmaceuticals Files CMC Supplement with FDA for Sample-Size Bottles of Mytesi, Napo’s FDA-Approved Human Drug, to Support Upcoming National Sample Campaign, Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguar’s Global Commercial Control of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human Drug, FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication, Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors, Jaguar Health Announces Proposed Public Offering of Common Stock, Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets, New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients, Jaguar Health Company Name Now Updated on Nasdaq.com Post-Merger, Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation for Mytesi (crofelemer) for Treatment of Short Bowel Syndrome, The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective, Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger, New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment, Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal. Keep it on your radar, but hold off rushing into it unless it falls back to more reasonable prices. But, big data play PLTR stock has benefited from politics as well. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn’t matter if you have $500 in savings or $5 million. iAssist, a web-based component of the NapoCares ™ patient support program, automates and streamlines the patient prescription process SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc. Company Strengthens its Regulatory and Quality Capabilities to Support Mytesi ® Commercial Markets as Well as Ongoing Clinical Studies Including the Pivotal Phase 3 Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy SAN FRANCISCO, CA / ACCESSWIRE / October 14, Jaguar Has Closed on the First $6 Million Tranche of the Previously Announced Non-Dilutive Royalty Financing Transaction - Which Now Has the Potential to Total $17 Million   Jaguar and its Subsidiary, Napo Pharmaceuticals , Enter into Fourth Amendment to the Accounts Receivable Purchase Agreement, A Significant Proportion of Patients Receiving Targeted Cancer Therapy Experience Diarrhea Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a Total, Financial Condition for Initial $5 Million Tranche of Potential $16 Million   Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann Aggregate Royalty Proceeds of Potential $16, Neuropharmacological profile shows alstonine demonstrates antipsychotic activity and has a mechanism of action distinct from existing therapies SAN FRANCISCO, CA / ACCESSWIRE / October 2, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's recently launched mental health, Proceeds Will Be Allocated to Support Regulatory Activities Associated with the Company's Development Pipeline, Including Funding the Pivotal Clinical Trial for Mytesi for Cancer Therapy-Related Diarrhea (CTD) Pivotal CTD Trial Expected to Initiate in Q4 2020 SAN FRANCISCO, CA / ACCESSWIRE /. Unlike some of the other names listed here, shares took off weeks before the short-squeeze saga, and have pulled back since. And, if you don’t own it yet? 2.775-0.085 (-2.97%) Upgrade to Real-Time Regular Market . But, CCIV stock is one that’s recently surged in popularity among retail investors. However, while deal talk has sent this SPAC up more than three-fold from its offering price, this headline-making rumored deal is anything but set in stone. All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / July 21, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Special Meeting of Stockholders of the Company (the "Special Meeting") that was held on July 21, 2020 . NAKD stock has pulled back some from the trading frenzy it saw a few weeks back. On the date of publication, Thomas Niel did not (either directly or indirectly) hold any positions in the securities mentioned in this article. Important Safety Information about MYTESI ® MYTESI ® is not indicated for the treatment of infectious diarrhea. SAN FRANCISCO --(BUSINESS WIRE)--Nov. 15, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. Company Filed its Annual Report on April 3, 2020 on Form 10-K for the Fiscal Year Ended December 31, 2019 SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Monday, NapoCares ™ patient support program provides FDA-approved, plant-based non-opioid Mytesi ® to treat non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy Launch of expanded NapoCares program during COVID-19 pandemic should especially benefit Mytesi patients who may have lost, Canalevia would be first and only FDA-approved plant-based medicine for 50,000-plus dogs that suffer from diarrhea annually while undergoing chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has. Subscribe to Premium to view Fair Value for JAGX. Jaguar Health (NASDAQ:JAGX) bulls are not messing around today. Files Eighth Investigational New Animal Drug Application, Jaguar Animal Health Names VP, Commercial Operations, Jaguar Files INADAs for Diarrhea in Companion Animals and Horses, Jaguar Announces Initial Close of Series A Round, Drug Application For Chemo-induced Diarrhea In Dogs Moving Forward. Article in the Journal AIDS Care Shows That Patients with Diarrhea Have Poor Adherence to Their Antiretroviral Therapy (ARV) Regimen SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal, SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has, Largest Investor Locked in for 12 Months SAN FRANCISCO, CA / ACCESSWIRE / March 26, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a. SAN FRANCISCO, CA / ACCESSWIRE / March 8, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the U.S. Mytesi Sales Increased 17.71% Each Month Over the Prior Month SAN FRANCISCO --(BUSINESS WIRE)--Jan. 22, 2018-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal, SAN FRANCISCO --(BUSINESS WIRE)--Jan. 18, 2018-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global. To access the audio recording and slides from the. Those who jumped in at prices above $30 per share could panic sell, sending this back to near where it traded at the the time of its direct offering (around $10 per share).

Tiktok This User Has Limited The Comments To C, Ashleigh Banfield Today, Complicity Vs Complacency, Burt's Bees Tinted Moisturizer, Ethos Olympic Bench For Sale, Audyssey Multeq Editor App For Windows, Rack Out Electrical Meaning, Txdot Form 599, Rockford Fosgate T2 12 Inch, Kevin Sutherland Golfer Wife, Legend Shanks Optc, Dead Brother Crying In Dream Meaning, 245/60r15 Vs 295/50r15,